<DOC>
	<DOCNO>NCT00960531</DOCNO>
	<brief_summary>The purpose study assess long term safety , tolerability , immunogenicity ACC-001 , investigational vaccine , plus QS-21 subject mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>A Long Term Extension Study Evaluating ACC-001 With QS-21 Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Subjects randomize previous 3134K12201 study ( NCT00498602 ) meet inclusion/and none exclusion criterion . Screening brain MRI scan consistent diagnosis AD . MiniMental State Examination ( MMSE ) score great equal 10 . Other criterion apply . Significant Neurological Disease Alzheimer 's disease . Current clinically significant systemic illness . Other exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>